Events
amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, will present a poster on the mode of action of its lead candidate AMC303 at the upcoming American Association for Cancer Research Annual Meeting.
Probiodrug AG announced its financial results for the twelve-month period ending December 31, 2018, prepared in accordance with German GAAP and on a voluntary basis, in accordance with IFRS as endorsed by the European Union.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Conference call and webcast, March 27, 2019 at 3pm CET (Frankfurt) / 10am EST (New York)
Heidelberg Pharma AG announced that it will present preclinical data on the application of its proprietary ATAC technology platform in the treatment of triple-negative breast cancer at the Annual Meeting of the American Association for Cancer Research 2019.
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
Therigy announced that the company will present a poster from its recently completed quality initiative: “Improving Quality of Care in Rheumatoid Arthritis Utilizing Hospital-Based Specialty Pharmacies in Monitoring Disease Activity,” at the AMCP Managed Care and Specialty Pharmacy 2019 Annual Meeting being held March 25-28, 2019 in San Diego, California.
Theralase Technologies Inc. is pleased to announce that the results of the Phase Ib clinical study will be presented at the 17th International Photodynamic Association World Congress, to be held in Cambridge, Massachusetts from June 28th to July 4th, 2019.
The shareholders of Immunicum AB, reg. no 556629-1786, are hereby invited to the Annual General Meeting on Thursday, 25 April 2019, at 10:30, at Sturegatan 15’s premises, at Sturegatan 15, SE-161 14 36 Stockholm.
Numerous top biopharma executives met recently in Manalapan, Florida for the R&D Leadership Summit. Although a wide range of topics were discussed, certain areas rose to the top as being of particular concern to industry leadership. Here’s a look at a few of those concerns.
PRESS RELEASES